Table 2.
Canonical pathways enriched by differentially expressed proteins in MAIT cells compared to Non-MAIT T cells.
| Ingenuity Canonical Pathways | Log2 fold-change | Over-expressed | Under-expressed | Quantified proteins | |
|---|---|---|---|---|---|
| MAIT cells vs non-MAIT CD3+ T cells | B cell receptor signalling | 1.4 | 9/192 (5 %) | 1/192 (1 %) | MAP2K6, RRAS2, JUN, INPPL1, GSK3A, MAP3K4, INPP5K, GSK3B, MALT1, NFKBIB |
| 14-3-3-mediated signalling | 1.4 | 8/131 (6 %) | 0/131 (0 %) | RRAS2, JUN, TUBB6, TUBB8, PRKCD, EDC3, GSK3A, GSK3B | |
| CD40 signalling | 1.4 | 5/79 (6 %) | 1/79 (1 %) | MAP2K6, TANK, JUN, TNFAIP3, MAPKAPK2, NFKBIB | |
| TNFR2 signalling | 1.4 | 4/30 (13 %) | 0/30 (0 %) | TANK, JUN, TNFAIP3, NFKBIB | |
| Regulation of IL-2 in activated and anergic T-cells | 1.4 | 6/80 (8 %) | 0/80 (0 %) | RRAS2, JUN, CHP1, SMAD4, MALT1, NFKBIB | |
| Protein kinase A signalling | 1.39 | 11/401 (3 %) | 3/401 (1 %) | CHP1, PTPN18, PPP1R11, GSK3A, PTPN12, AKAP11, PTPRJ, PRKCD, SMAD4, LEF1, H1F0, GSK3B, NFKBIB, PDE6D | |
| TNRF2-mediated oxidative stress response | 1.38 | 8/193 (4 %) | 1/193 (1 %) | MAP2K6, DNAJC17, RRAS2, JUN, PRKCD, JUNB, GSK3B, SQSTM1, DNAJC11 | |
| 3-phosphoinositide degradation | 1.38 | 7/157 (4 %) | 1/157 (1 %) | PTPRJ, PIP4P1, NUDT16, EPHX2, INPPL1, INPP5K, NUDT2, PTPN12 | |
| MAIT cells vs non-MAIT CD8+ T cells | CD40 signalling | 1.44 | 5/79 (6 %) | 1/79 (1 %) | MAP2K6, TANK, JUN, TNFAIP3, MAPKAPK2, TRAF1 |
| TNFR2 signalling | 1.44 | 3/30 (10 %) | 1/30 (3 %) | TANK, JUN, TNFAIP3, TRAF1 | |
| Thiosulfate disproportionation III (Rhodanese) | 1.44 | 2/3 (66 %) | 0/3 (0 %) | MPST, MOCS3 | |
| Protein kinase A signalling | 1.44 | 6/401 (1 %) | 7/401 (2 %) | NFATC3, CHP1, PTPN18, PPP1R11, ITPR1, PTPN12, AKAP11, HIST1H1A, PTPRJ, PRKCD, PRKAR1B, LEF1, H1F0 | |
| CD28 signalling in Th cells | 1.42 | 2/132 (2 %) | 5/132 (4 %) | JUN, NFATC3, CD4, CHP1, ITPR1, MALT1, ITK |